PFE
PfizerNYSEHealth CareDrug Manufacturers - GeneralSnapshot 2026-05-08
As of May 8, 2026, PFE has a composite score of 20.9 and a signal label of "mild favorable." This score is influenced by a medium confidence level of 75.1 and a low risk label. Key drivers include macroeconomic factors such as labor, rates, growth, and inflation, with sector performance also impacting the overall assessment. The current analysis is provisional.
Price
Daily closes from AlphaVantage. Earnings/event dots are placed inline.
Factor signals
Read top-to-bottom: thesis (is this a strong company over a 1–3 year hold), watch flags (has something changed worth re-reading), and position context (how violent might the path be). Each pill is a parallel diagnostic — never aggregated into a single score.
Thesis
— is this a strong company over a 1–3 year hold?Why this rank
- Direction share0.69
- Slope (norm)-0.53
- Bonus0.00
Why this rank
Trailing four: 2024-Q3, 2025-Q1, 2025-Q2, 2025-Q3
Why this rank
Watch
— has something changed worth re-reading?Buyback / dividend activity on weakening fundamentals — historically a value-trap pattern (48% T+1y positive return vs 69% baseline in IT 2024-26).
Why this setup
EPS estimate $0.70 → $0.68 (-2.5% / 30d). 4 raised, 10 cut, 18 covering analysts.
0 upgrades, 0 downgrades / 30d, 5 maintained. 38% of analysts rate Buy.
0 positive, 0 negative / 30d.
F4 · Management deep-dive — recent events, stated priorities, guidance track record
Recent 8-K events
3 material events in the last 24 months — top 3 listed below.
Stated priorities
3 priorityies extracted from earnings transcripts (as of 2026-05-08).
- 1.Achieve $5.7B net cost savings by 2027costwatchprovisional
4/29: “Pfizer announced it remains on track to deliver net cost savings of approximately $4.5 billion by the end of 2025.”
Why this status
Newly stated in 2025-Q1. Pfizer aims to achieve $5.7 billion in net cost savings by 2027, with $4.5 billion expected by the end of 2025. The financials show a net income decline from $3.1 billion in 2025-Q1 to a loss of $1.5 billion in 2025-Q4, indicating limited progress towards cost savings.
- 2.Reaffirm full-year 2026 revenue guidancegrowthmixed65% progress
5/5: “Today, we are reaffirming our full-year 2026 financial guidance.”
Why this status
Stated in 3 of last 3 quarters. Pfizer reaffirmed its 2026 revenue guidance at $59.5 to $62.5 billion. Revenue was $17.44 billion in 2025-Q4, down from $17.76 billion in 2024-Q4, indicating a challenging trajectory to meet the guidance.
- 3.Reaffirm full-year 2026 EPS guidancegrowthmixed65% progress
5/5: “Today, we are reaffirming our full-year 2026 financial guidance.”
Why this status
Stated in 3 of last 3 quarters. Pfizer reaffirmed its 2026 EPS guidance at $2.80 to $3.00. EPS was $0.62 in 2025-Q3, down from $0.78 in 2024-Q3, indicating limited progress towards achieving the guidance.
Guidance track record
Insufficient guidance history for this ticker.
Position context
— how violent might the path be while I hold it?Why this risk level
Recent vol — 30d annualized 22%; 252d 25%.
Drawdown — Max 1y −11%. Bad day move −2%.
Beta to sector ETF (XLV) — 0.99 over 1y.
Liquidity — score 100/100.
Sub-scores — vol 59/100, drawdown 77/100, beta 99/100, earnings vol —.
via XLV
Tailwind = sector leading the S&P 500; headwind = trailing. Both can be constructive — historically, headwind regimes have averaged stronger forward returns than tailwind.
Context label only — describes the market state (e.g. real bear vs narrative panic, healthy uptrend vs late-stage froth). It is not a per-ticker buy/sell signal and does not predict factor performance.
Not investment advice. As of 2026-05-08.
What changed
The most important moves since the prior daily snapshot.
- No material changes since the prior snapshot.
No material changes since the prior snapshot.
as of 2026-05-08
Management scorecard
How management runs the business — capital, margins, balance sheet, and how reliably they guide and deliver.
What management is focused on
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
- #1
Achieve $5.7B net cost savings by 2027
CostPfizer aims to achieve total net cost savings of approximately $5.7 billion from its cost-saving program by 2027.
WatchNewly stated in 2025-Q1. Pfizer aims to achieve $5.7 billion in net cost savings by 2027, with $4.5 billion expected by the end of 2025. The financials show a net income decline from $3.1 billion in 2025-Q1 to a loss of $1.5 billion in 2025-Q4, indicating limited progress towards cost savings.
No scoreCEO/CFO:“Pfizer announced it remains on track to deliver net cost savings of approximately $4.5 billion by the end of 2025.”Multiple sourcesSource dated 2025-04-29Stated 1 of last 8 quartersFirst seen 2025-04-29provisionalShow history (1)
- 2025-Q1Multiple sources
“Pfizer announced that it remains on track to deliver net cost savings of approximately $4.5 billion by the end of 2025.”
- #2
Reaffirm full-year 2026 revenue guidance
GrowthNew since 2026-05-05Pfizer reaffirms its full-year 2026 revenue guidance in the range of $59.5 to $62.5 billion.
MixedStated in 3 of last 3 quarters. Pfizer reaffirmed its 2026 revenue guidance at $59.5 to $62.5 billion. Revenue was $17.44 billion in 2025-Q4, down from $17.76 billion in 2024-Q4, indicating a challenging trajectory to meet the guidance.
65%CEO/CFO:“Today, we are reaffirming our full-year 2026 financial guidance.”Multiple sourcesSource dated 2026-05-05Stated 3 of last 8 quartersFirst seen 2026-05-05Show history (3)
- 2026-Q2Multiple sources
“Today, we are reaffirming our full-year 2026 financial guidance.”
- 2026-Q1Multiple sources
“Today, we are reaffirming our full-year 2026 financial guidance.”
- 2025-Q4Multiple sources
“Pfizer anticipates full-year 2026 revenues to be in the range of $59.5 to $62.5 billion.”
- #3
Reaffirm full-year 2026 EPS guidance
GrowthNew since 2026-05-05Pfizer reaffirms its full-year 2026 EPS guidance in the range of $2.80 to $3.00.
MixedStated in 3 of last 3 quarters. Pfizer reaffirmed its 2026 EPS guidance at $2.80 to $3.00. EPS was $0.62 in 2025-Q3, down from $0.78 in 2024-Q3, indicating limited progress towards achieving the guidance.
65%CEO/CFO:“Today, we are reaffirming our full-year 2026 financial guidance.”Multiple sourcesSource dated 2026-05-05Stated 3 of last 8 quartersFirst seen 2026-05-05Show history (3)
- 2026-Q2Multiple sources
“Today, we are reaffirming our full-year 2026 financial guidance.”
- 2026-Q1Multiple sources
“Today, we are reaffirming our full-year 2026 financial guidance.”
- 2025-Q4Multiple sources
“Pfizer anticipates full-year 2026 Adjusted (1) diluted EPS to be in a range of $2.80 to $3.00.”
How this stock is priced
Two ways to read price: against peers in the same business, and against the company's own history.
Looks cheaper than most peers in the same business.
Cheaper than its own typical valuation.
P/E over the last 5 years
59 monthly pointsHow this compares
A side-by-side read on composite, valuation, and risk versus peers.
| Stock | Composite | Valuation | Risk |
|---|---|---|---|
PFE Pfizer | +21 | inexpensive | low |
LLY Lilly (Eli) | +21 | full | moderate |
JNJ Johnson & Johnson | +18 | full | low |
ABBV AbbVie | +12 | fair | low |
UNH UnitedHealth Group | +24 | fair | elevated |
Risk — how this stock moves
What a normal day looks like, what a bad day looks like, and the worst the last year has thrown at it.
What could change this view
Conditional scenarios — if X happens, the score would shift by about Y points. These are not predictions.
- If health_care sector trend rises from +0.06 into 'improving' (>= +0.20)+5.0 pts
- If next-quarter guidance is raised (currently REAFFIRMED as of 2026-05-05)+4.0 pts
- If next-quarter guidance is cut (currently REAFFIRMED as of 2026-05-05)-8.0 pts
- If labor state reverses from -0.31 (negative) to +0.31 (positive)-6.8 pts
- If health_care sector trend falls from +0.06 into 'weakening' (<= -0.20)-5.0 pts
Material updates
Recent SEC 8-K filings ranked by likely impact, confidence, and recency.
- 2026-05-053d agoItem 2.02
Results of Operations and Financial Condition”, including Exhibit 99, shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference into any filing made by us under the Exchange Act or Securities Act of 1933, as amended, regardless of any general incorporation language in any such filing, except as shall be…
earnings preannouncementneutralscore 61 - 2026-02-033mo agoItem 2.02
Results of Operations and Financial Condition”, including Exhibit 99, shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference into any filing made by us under the Exchange Act or Securities Act of 1933, as amended, regardless of any general incorporation language in any such filing, except as shall be…
earnings preannouncementpositivescore 8 - 2025-11-135mo agoItem 8.01
Results of Other Events On November 13, 2025, Pfizer Inc. (“Pfizer” or the “Company”) completed the previously announced acquisition of Metsera, Inc., a Delaware corporation (“Metsera”), pursuant to the Agreement and Plan of Merger, dated as of September 21, 2025, as amended by Amendment No. 1 to the Agreement and Plan of Merger, dated as of November 7, 2025, by and among the Company, Metsera and Mayfair Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of the Company (as a…
mna activitypositivescore 1
Score history
The composite score, snapshot by snapshot. The dotted line at zero separates leaning-positive from leaning-negative.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.